Daniel Castellano

40.8k total citations · 6 hit papers
368 papers, 9.5k citations indexed

About

Daniel Castellano is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel Castellano has authored 368 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Oncology, 201 papers in Pulmonary and Respiratory Medicine and 132 papers in Surgery. Recurrent topics in Daniel Castellano's work include Bladder and Urothelial Cancer Treatments (114 papers), Renal cell carcinoma treatment (99 papers) and Cancer Immunotherapy and Biomarkers (93 papers). Daniel Castellano is often cited by papers focused on Bladder and Urothelial Cancer Treatments (114 papers), Renal cell carcinoma treatment (99 papers) and Cancer Immunotherapy and Biomarkers (93 papers). Daniel Castellano collaborates with scholars based in Spain, United States and United Kingdom. Daniel Castellano's co-authors include Joaquim Bellmunt, Elizabeth R. Plimack, Ronald de Wit, Thomas Powles, Petros Grivas, Peter H. O’Donnell, Ignacio Durán, Arjun Vasant Balar, Dean F. Bajorin and Jacqueline Vuky and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel Castellano

348 papers receiving 9.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

2017 939 citations Arjun Vasant Balar, Daniel Castellano et al. profile →
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2021 670 citations Thomas Powles, Yohann Loriot et al. New England Journal of Medicine profile →
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019 377 citations Ronald de Wit, Johann S. de Bono et al. New England Journal of Medicine profile →
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

2020 347 citations Laurence Albigès, David F. McDermott et al. profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

2023 84 citations Thomas Powles, Yohann Loriot et al. profile →

Peers

Countries citing papers authored by Daniel Castellano

Since Specialization

Citations

This map shows the geographic impact of Daniel Castellano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Castellano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Castellano more than expected).

Fields of papers citing papers by Daniel Castellano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Castellano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Castellano. The network helps show where Daniel Castellano may publish in the future.

Co-authorship network of co-authors of Daniel Castellano

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Castellano. A scholar is included among the top collaborators of Daniel Castellano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Castellano. Daniel Castellano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS. 2025 ·Journal of Clinical Oncology ·Joan Carles, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Á. Montesa Pino, (unknown), Alejo Rodríguez‐Vida, Daniel Castellano, Pablo Borrega, (unknown), (unknown), (unknown), Matthew R. Smith	0
2	Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study 2024 ·European Urology Oncology ·Xavier García del Muro, D. Páez López-Bravo, (unknown), Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel Ángel Climent, Begoña P. Valderrama, Alfonso Gómez de Liaño, (unknown), Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi	6
3	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 2024 ·Clinical Cancer Research ·Neeraj Agarwal, Daniel Castellano, Teresa Alonso‐Gordoa, Jóse Ángel Arranz Arija, Émeline Colomba, Gwénaëlle Gravis, Loı̈c Mourey, Stéphane Oudard, Aude Fléchon, (unknown), Pablo Maroto, Michael T. Schweizer, Enrique Gallardo, (unknown), Arjun Vasant Balar, Nadine Haddad, Adams K. Appiah, (unknown), Josep M. Piulats	6
4	Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma 2023 ·European Urology ·Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan	61
5	Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival 2023 ·European Journal of Endocrinology ·Anna La Salvia, (unknown), (unknown), (unknown), Jaume Capdevila, Marta Benavent, Paula Jiménez‐Fonseca, Daniel Castellano, Teresa Alonso, Àlex Teulé, Ana Custodio, Salvatore Tafuto, Adelaida La Casta, Francesca Spada, Ángeles López‐Gonzálvez, (unknown), (unknown), Coral Barbas, Rocio García‐Carbonero, Beatriz Soldevilla	6
6	Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC). 2023 ·Journal of Clinical Oncology ·Cora N. Sternberg, Yohann Loriot, Ernest Choy, Daniel Castellano, (unknown), Giuseppe Luigi Banna, Ugo De Giorgi, Cristina Masini, Aristotelis Bamias, Xavier García del Muro, Ignacio Durán, Thomas Powles, Marija Gamulin, Friedemann Zengerling, Lajos Géczi, Craig Gedye, Robert Huddart, (unknown), Pari Skamnioti, Axel S. Merseburger	1
7	Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis 2022 ·OncoImmunology ·Alberto Carretero-González, Marta Hergueta‐Redondo, Sara Sánchez‐Redondo, Pilar Ximénez‐Embún, Luís Manso, Eva Ciruelos, Daniel Castellano, Guillermo de Velasco, Héctor Peinado	19
8	A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial 2022 ·European Journal of Cancer ·Miguel Ángel Climent, Albert Font, Ignacio Durán, Javier Puente, María José Méndez-Vidal, M.I. Sáez, (unknown), Jóse Ángel Arranz Arija, Aranzazu González del Alba, (unknown), María José Juan-Fita, Emilio Esteban, Teresa Alonso‐Gordoa, B. Mellado González, Pablo Maroto, Martín Lázaro-Quintela, (unknown), Begoña Pérez‐Valderrama, (unknown), Daniel Castellano	9
9	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma breakdown → 2021 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, (unknown), В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Frédéric Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	183
10	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib 2021 ·British Journal of Urology ·Guillermo de Velasco, (unknown), Òscar Reig, Francesco Massari, Miguel Á. Climent Durán, Elena Verzoni, Jeffrey Graham, Roberto Llarena, Michele De Tursi, Frede Donskov, (unknown), Hardev Pandha, Xavier García del Muro, Giuseppe Procopio, Stéphane Oudard, Daniel Castellano, Laurence Albigès	2
11	Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy 2020 ·Cancers ·Albert Font, Montserrat Domènech, Raquel Benítez, Marta Rava, Miriam Marqués, José Luis Ramírez, Sílvia Pineda, Sara Domínguez‐Rodríguez, (unknown), Josep Badal, Cristina Carrato, (unknown), (unknown), Daniel Castellano, Núria Malats, Francisco X. Real	34
12	Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials 2020 ·Clinical & Translational Oncology ·Alberto Carretero-González, David Lora, Ray Manneh Kopp, David Lorente, Daniel Castellano, Gloria Velasco	4
13	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer breakdown → 2019 ·New England Journal of Medicine ·Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Daniel Castellano	377
14	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial 2018 ·Journal of Clinical Oncology ·Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frédéric Rolland, Piotr Tomczak, Daniel Castellano, Leonard J. Appleman, Harry A. Drabkin, Daniel A. Vaena, Steven Milwee, (unknown), Julie C. Lougheed, Sergio Bracarda, Toni K. Choueiri	121
15	BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer 2017 ·Clinical Cancer Research ·Víctor G. Martínez, Carolina Rubio, Mónica Martínez‐Fernández, Cristina Segovia, Fernando López-Calderón, Marina Garín, Alicia Teijeira, Ester Munera-Maravilla, Alberto Varas, Rosa Sacedón, Félix Guerrero‐Ramos, Felipe Villacampa, Federico de la Rosa, Daniel Castellano, Eduardo López‐Collazo, Jesús M. Paramio, Ángeles Vicente, Marta Dueñas	159
16	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature 2015 ·BMC Urology ·Vicente Guillém, Miguel Ángel Climent, Javier Cassinello, Emilio Esteban, Daniel Castellano, J.L. González-Larriba, Pablo Maroto, Carlos Camps	1
17	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer 2014 ·Clinical Cancer Research ·Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen‐Chuan Ou, Daniel Castellano, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, (unknown), Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin	49
18	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Eric Angevin, José A. López-Martín, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean‐Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier	103
19	Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) 2012 ·Pancreas ·Aaron I. Vinik, Eric Van Cutsem, Patricia Niccoli, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Jen‐Shi Chen, Dieter Hoersch, Daniel Castellano, Hagen F. Kennecke, Joel Picus, Guy van Hazel, Shem Patyna, Dongrui R. Lu, Richard C. Chao, Éric Raymond	4
20	Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo 2011 ·Pancreas ·Pascal Hammel, Daniel Castellano, Eric Van Cutsem, Patricia Niccoli, Sandrine Faivre, Shem Patyna, (unknown), Dongrui R. Lu, Richard C. Chao, Éric Raymond	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact